ArticlePloS one2025
Cost profiles of cancer patients at the end of life: Estimates from the EPICOST-study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Direct Hospitalisation Costs of End-of-Life Cancer Care: Comparison Between Usual Care and Palliative Care Consultation.Healthcare (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe study aims to analyze care and cost patterns in the Veneto region for cancer patients in the final phase of their disease.
methodsThe study cohort includes adult patients alive on 1.1.2018, which have been diagnosed with cancer at the age 15+ in a 28-years period, spanning from 1990 to 2017, and died within 12 months from prevalence date. The end-of-life (EOL) prevalent cases included in the study cohort are identified by the Veneto Tumor Registry. Primary tumors considered in the analysis are colon, rectum, skin melanoma, female breast, thyroid. Patient monthly average EOL costs, patient annual average EOL costs and total regional costs have been estimated separately for each cancer site/sex/age group/health care service database.
resultsThe estimated EOL total cost, for the five analyzed cancer types in the Veneto Region, is approximately 53 million euros. Costs associated with cancer treatment tend to increase in the final phase of the disease. In general, Hospital Admission is the main driver cost in all types of cancer considered, with the only exception in melanoma, where Hospital Drugs features the highest contribution. Moreover, costs differ significantly depending on the type of cancer, gender, and age, revealing highest average costs associated with younger patients.
conclusionsThis study provides a comprehensive analysis of healthcare budget distribution in the last year of life, enabling healthcare planners to predict cancer burden in the future. This model can be applied to other Italian regions and countries with different healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.